RPg Family Wealth Advisory LLC grew its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 3.6% in the first quarter, Holdings Channel reports. The fund owned 16,652 shares of the medical research company’s stock after buying an additional 572 shares during the period. RPg Family Wealth Advisory LLC’s holdings in PRA Health Sciences were worth $1,837,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Thrivent Financial for Lutherans boosted its position in PRA Health Sciences by 7.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 14,975 shares of the medical research company’s stock worth $1,377,000 after acquiring an additional 1,068 shares during the period. Tekla Capital Management LLC lifted its holdings in shares of PRA Health Sciences by 117.1% in the fourth quarter. Tekla Capital Management LLC now owns 70,460 shares of the medical research company’s stock valued at $6,480,000 after buying an additional 38,000 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in shares of PRA Health Sciences by 2.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 8,700 shares of the medical research company’s stock valued at $800,000 after buying an additional 240 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of PRA Health Sciences by 13.9% in the first quarter. Janus Henderson Group PLC now owns 90,053 shares of the medical research company’s stock valued at $9,932,000 after buying an additional 10,994 shares during the period. Finally, Barclays PLC lifted its holdings in shares of PRA Health Sciences by 52.7% in the fourth quarter. Barclays PLC now owns 38,121 shares of the medical research company’s stock valued at $3,505,000 after buying an additional 13,162 shares during the period. Institutional investors and hedge funds own 99.43% of the company’s stock.

Several analysts have recently weighed in on the company. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. Mizuho set a $100.00 price objective on PRA Health Sciences and gave the company a “hold” rating in a report on Friday, May 3rd. SunTrust Banks upped their price objective on PRA Health Sciences to $120.00 and gave the company an “average” rating in a report on Monday, March 4th. ValuEngine lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. Finally, Wolfe Research assumed coverage on PRA Health Sciences in a report on Tuesday, April 2nd. They issued a “market perform” rating for the company. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $113.22.

Shares of NASDAQ PRAH traded up $0.76 during mid-day trading on Wednesday, hitting $95.96. 12,706 shares of the company traded hands, compared to its average volume of 540,657. PRA Health Sciences Inc has a 1 year low of $82.12 and a 1 year high of $121.98. The company has a market cap of $6.11 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.26 and a beta of 1.08. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.97.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, May 1st. The medical research company reported $1.10 EPS for the quarter, beating the consensus estimate of $0.95 by $0.15. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The business had revenue of $722.00 million during the quarter, compared to the consensus estimate of $730.84 million. During the same period in the prior year, the business posted $0.85 earnings per share. PRA Health Sciences’s revenue was up 2.9% compared to the same quarter last year. As a group, sell-side analysts expect that PRA Health Sciences Inc will post 4.63 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “PRA Health Sciences Inc (NASDAQ:PRAH) Shares Bought by RPg Family Wealth Advisory LLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2019/06/12/pra-health-sciences-inc-nasdaqprah-shares-bought-by-rpg-family-wealth-advisory-llc.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: What is the Bid-Ask Spread?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.